Everolimus vs Nothing as Treatment for Kidney Cancer After Kidney Surgery
The purpose of this study is to see how well everolimus works as a prevention treatment for kidney cancer patients who have undergone surgery to remove all or part of a kidney.
The primary objective is to determine if everolimus works better than taking nothing for preventing kidney cancer from coming back after surgery. The study will enroll 1170 participants from many cancer centers in the US.
In addition to other conditions for enrollment, patients have a diagnosis of renal cell or clear cell kidney cancer but no evidence of cancer in other parts of the body. Eligible patients have recovered from the kidney surgery and have not received any other treatment for their cancer. Eligible patients are able to take oral medications and do not have any digestive problem that would affect how well a drug is digested. Patients are not eligible if they have uncontrolled diabetes, impaired liver function, or impaired breathing function.
To enroll or if you have questions about participation